World Health Organization site
Skip Navigation Links

Main
Note: This record shows only 21 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Register: ClinicalTrials.gov
Last refreshed on: 14 January 2019
Main ID:  NCT03052998
Date of registration: 10/02/2017
Prospective Registration: Yes
Primary sponsor: Robert Colebunders
Public title: Ivermectin Treatment in Patients With Onchocerciasis-associated Epilepsy OAETREAT
Scientific title: Ivermectin Treatment in Patients With Onchocerciasis-associated Epilepsy: A Randomized Clinical Trial
Date of first enrolment: October 1, 2017
Target sample size: 91
Recruitment status: Completed
URL:  https://clinicaltrials.gov/show/NCT03052998
Study type:  Interventional
Study design:  Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Single (Outcomes Assessor).  
Phase:  Phase 4
Countries of recruitment
Congo, The Democratic Republic of the
Contacts
Name:     Michel Mandro, MD
Address: 
Telephone:
Email:
Affiliation:  Chef de Bureau Inspection&Contrôle et Associé de Recherche Clinique
Key inclusion & exclusion criteria

Inclusion Criteria:

- Age 5 years and above

- Signed informed consent form

- Normal neurological development until onset of epilepsy

- Onset of epilepsy between ages of 5 and 18 years

- Seizure frequency of =2 seizures per month

- Presence of microfilaria in skin snip and/or antibodies against Ov16

Exclusion Criteria:

- Ivermectin intake the last 9 months

- Pregnancy or breastfeeding

- Known or suspected allergy to Ivermectin

- Loa Loa microfilariae in blood

- Epilepsy with known cause (e.g. severe head trauma, perinatal asphyxia, patients with
a history of cerebral malaria, meningitis or encephalitis)



Age minimum: 5 Years
Age maximum: N/A
Gender: All
Health Condition(s) or Problem(s) studied
Epilepsy
Ivermectin
Onchocerciasis
Intervention(s)
Drug: Ivermectin
Primary Outcome(s)
seizure freedom [Time Frame: 4 months]
Secondary Outcome(s)
>50 % reduction in seizure frequency [Time Frame: 4 months]
Secondary ID(s)
B300201730821
ERC grant No.671055
Source(s) of Monetary Support
Please refer to primary and secondary sponsors
Secondary Sponsor(s)
Ethics review
Results
Results available:
Date Posted:
URL:
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.6 - Version history